Clinical Study

A Study Of Hsp90 Inhibitor At13387 Alone And In Combination With Crizotinib In The Treatment Of Non-Small Cell Lung Cancer (Nsclc)

Posted Date: May 15, 2019

  • Investigator: Nagla Abdel Karim
  • Specialties:
  • Type of Study: Drug

This study is designed to evaluate AT13387 (the study drug) alone or in combination with Crizotinib in subjects with Non-small cell lung cancer (NSCLC). The study drug that will be used in this study, (AT13387), is investigational. This means it has not been approved for use by the United States

Criteria:

To Be Eligible For The Study You Must Have Non-Small Cell Lung Cancer (Nsclc).

Keywords:

Cancer, Lung, At13387-05, Combination, Nsclc

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.